Sun Pharma’s steady India business and US specialty portfolio should help it do well in FY22

Sun Pharma’s steady India business and US specialty portfolio should help it do well in FY22 What adds to the Sun Pharma#39;s investment case is the prospect for US specialty. The management hopes to achieve EBITDA break-even for a few products next fiscal